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Abstract
Background: Age has been a critical predictor for immediate postoperative and long-term results after the pulmonary
resection for lung cancer. In this study, we evaluated and compared surgical outcome of stage I non-small cell lung
cancer and associated predictive factors between elderly and younger groups.
Methods: Short- and long-term outcomes of elderly group (≥70 years) who were surgically treated and pathologically
diagnosed as stage I non-small cell lung cancer from 2004 to 2010 were compared to the results of younger group
(<70 years).
Results: Total of 1340 patients were included in this study, and the patients were divided into the elderly group (n = 285)
and the younger group (n= 1055). The proportions of squamous cell carcinoma (36.8 vs. 20.0 %, p < 0.001) and stage IB
cancer (58.3 vs. 40.6 %, p < 0.001) were significantly higher in the elderly group than the younger group. The 30-day and
90-day mortalities were significantly higher in the elderly group (1.8 vs. 0%; p = 0.014, 3.9 vs. 0.5 %; p < 0.001, respectively).
The elderly patients also had significantly worse long-term outcomes than the younger group (5-year overall survival rate,
69.0 vs. 91.1 %; p < 0.001, 5-year disease-free survival rate, 53.3 vs. 80.2 %; p < 0.001). Decreased diffusion capacity less than
70 % was an important predictive factor for short- and long-term outcomes in both the younger and the elderly group.
Conclusions: Elderly patients with low diffusion capacity are at risk for significantly worse outcome, indicating
that patient selection should include assessment of pulmonary function, including diffusion capacity.
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Background
Lung cancer is a dreadful disease, but better results can
be obtained with early detection and effective surgery.
Accordingly, considerable effort has been devoted to
early diagnosis of lung cancer. Lung cancer is the second
most common cancer for those aged 70 years or older,
and the likelihood of developing new lung cancer was 1
in 15 for males and 1 in 20 for females in the USA in
2013 [1]. Rapid expansion of the geriatric population in
both developed and developing countries has increased
the number of cases of newly diagnosed lung cancer in
elderly patients, and lung cancer has literally become a
“disease of elderly people” [2].
However, surgical treatment, the gold standard in early
lung cancer, is not always recommended for elderly pa-
tients compared to younger patients. According to the
previous studies, only less than 50 % of patients older
than 75 years were rendered to undergo surgical resec-
tion even for early non-small cell lung cancer (NSCLC)
for a variety of reasons, including comorbidities and per-
sonal decisions not to pursue further treatment [3, 4].
On the other hand, a few encouraging results of success-
ful surgery in octogenarians or nonagenarians with early
lung cancer have been reported [5–7]. Even so, most
existing studies were conducted in highly selected pa-
tient populations and focused mainly on early outcomes,
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making them insufficient to justify recommending for or
against surgery in elderly patients in general.
To confirm that pulmonary resections in elderly patients
are as safe as in younger patients, it is important to com-
pare surgical outcomes and also associated predictors.
Furthermore, if elderly patients show worse outcomes, it
is important to identify not only common predictive fac-
tors in both age groups but also age-specific factors, and
this would be helpful to establish more elderly-specific
guideline for selecting surgery patients. In this study, we
evaluated and compared short- and long-term outcomes
of elderly and younger patients who underwent pulmon-
ary resection for stage I NSCLC and analyzed common
predictive factors and specific factors for both age groups.
Methods
Patients and data collection
This was a retrospective observational study performed
in a single center and approved by the hospital’s institu-
tional review board. From January 2004 to December
2010, 3033 patients were surgically treated with curative
intent for primary lung cancer, and 1787 patients were
pathologically diagnosed with stage I NSCLC. Patients
with synchronous double primary lung cancer (n = 49),
previous history of other malignancy (n = 162) and those
without mediastinal lymph node dissection (n = 145)
were excluded from the study. Patients with histologic
subtypes other than adenocarcinoma, squamous cell car-
cinoma, or large cell neuroendocrine carcinoma were
also excluded (n = 107).
A total of 1340 patients were enrolled, with 285 patients
(21.3 %) in the elderly group (≥70 years) and 1055 patients
(78.7 %) in the younger group (<70 years). Significant cut-
off value of age groups by 5 years for 30-day mortality and
overall survival was analyzed by a minimal p value ap-
proach. Data on clinical, surgical, and pathologic charac-
teristics were collected. Preoperative pulmonary function
tests included forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), FEV1/FVC, percentile
expected FEV1, percentile expected FVC, diffusing cap-
acity for carbon monoxide (DLCO), and percentile ex-
pected DLCO. Laboratory data including liver and kidney
function tests and ejection fraction from preoperative
echocardiography were also collected. The type of oper-
ation and extent of pulmonary resection were included as
surgical factors.
Surgical procedures and follow-up
The standard treatment for stage I NSCLC was lobectomy
or bi-lobectomy, in patients with limited pulmonary func-
tion or severe emphysema, segmentectomy or wedge re-
section was performed. After surgery, 4 patients (1.4 %)
from elderly group and 16 patients (1.5 %) from younger
group underwent adjuvant chemotherapy. The patients
visited the outpatient clinic and underwent computed
tomography or positron emission tomography/computed
tomography every 3 months for 2 years after the surgery
and then every 6 months for the next 3 years. The patients
visited the hospital annually after 5 years from the initial
operation. The median follow-up period was 47.6 months.
Patient survival was reviewed, and the end date was
defined as the date of latest follow-up or death. The
disease-free survival period was defined as the interval
from surgery to the first interpretation of recurrence in
an imaging study. Cancer recurrence was defined as car-
cinoma recurring in the lung or a distant organ and was
classified as loco-regional failure or distant failure ac-
cording to the initial site of recurrence. In detail, local
failure was defined as disease recurrence at the surgical
resection margin, regional failure as tumor recurrence in
the mediastinal, hilar, or supraclavicular lymph nodes,
and lung cancer in the ipsilateral lung, pleura, or chest
wall. Distant failure was defined as lung cancer other
than loco-regional failure or cancer metastasis in a dis-
tant organ. Metachronous double primary cancer was
defined according to modified Martini’s criteria and was
excluded from cancer recurrence. Newly appeared pure
ground glass opacity in the ipsilateral lung within 2 years
was also excluded from cancer recurrence.
The date of death for patients who expired during the
follow-up period was confirmed by our hospital (n = 64)
or National Cancer Registration Statistics (n = 89). Living
patients were followed-up in an outpatient clinic (n =
1163) or by telephone interview (n = 24) within 1 year of
data collection.
Statistical analyses
All data were statistically analyzed using STATA version
10 (2007, Stata Statistical Software: release 10; StataCorp
LP, College Station, TX). Ninety-five percent confidence
intervals corresponding to a 5 % significance level were
used. Mean values were compared using a Student t test
and median values by the Wilcoxon signed-rank test.
Data were interpreted in two categories. Short-term re-
sults, including 30-day and 90-day mortality, hospital
stay, in-hospital complication rate, and associated risk
factors, were evaluated by logistic regression model, and
there were no censored data during the follow-up period
of 90 days. Long-term results, including 5-year overall
and 5-year disease-free survival and 3-year cumulative
recurrence rate, were analyzed with Kaplan-Meier and
log-rank tests. Subgroup analyses for risk factors and
prognostic factors were evaluated in the elderly group
using Cox hazard modeling. For multivariate analyses,
backward selection of variables was performed. Vari-
ables with significance level >0.1 were eliminated from
the methods.
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Results
Patient characteristics
Median age of elderly group was 73 years (70–86) and of
younger group was 58 years (20–69). Male predominance
(p = 0.003) and the proportions of squamous cell carcin-
oma (36.8 % vs. 20.0 %, p < 0.001) and stage IB cancer
(58.3 vs. 40.6 %, p < 0.001) were significantly higher in the
elderly group than the younger group. There was no sig-
nificant difference in extent of pulmonary resection be-
tween the two groups, but open thoracotomy was more
frequently performed in elderly patients (55.4 vs. 37.8 %,
p < 0.001). Comparison of clinicopathologic features and
surgical procedures were demonstrated in Table 1.
Short-term results
The 30-day mortality rate was 6 of 1340 patients (0.4 %),
and all were elderly. Five patients died of acute respira-
tory distress syndrome (ARDS) and one from postopera-
tive pneumonia. The only independent factor for 30-day
mortality in the elderly group was DLCO less than 70 %
of prediction (low DLCO; odd ratio (OR) = 17.1, p =
0.024). Mortality within 90 days occurred for 16 patients
(1.2 %) and was significantly more frequent in the elderly
group (3.9 vs. 0.5 %, p < 0.001). Independent risk factors
for 90-day mortality included being elderly (OR = 2.0, p =
0.042) and low DLCO (OR = 3.9, p < 0.001). The elderly
group had significantly longer hospital stays (11.2 vs.
8.0 days, p < 0.001). The in-hospital complication rate was
also significantly higher in elderly patients (47.7 vs. 26.9 %,
p < 0.001). The most common major complications in the
elderly group were new onset of arrhythmia requiring
medicine (16.3 %) and acute lung injury or ARDS (5.7 %),
and independent risk factors were low DLCO (OR = 3.5,
p = 0.045) and male gender (OR = 7.8, p < 0.001).
Long-term results
Undoubtedly, elderly patients had significantly worse
long-term outcomes than the younger group (5-year over-
all survival rate; 69.0 vs. 91.1 %, p < 0.001, Fig. 1). Even so,
the difference between the two groups was much larger
than expected. In the multivariate analysis, independent
prognostic factors for overall survival after pulmonary re-
section of stage I NSCLC included elderly age (hazard
ratio (HR) = 3.6, p < 0.001), male gender (HR = 3.2, p =
0.005), interstitial pulmonary fibrosis (IPF; HR = 4.8, p <
0.001), and low DLCO (HR = 3.8, p < 0.001). Prognostic
factors for overall survival were summarized in Table 2.
For the subgroup analysis in the elderly group, inde-
pendent prognostic factors for overall survival included
histologic subtype of squamous cell carcinoma (HR =
3.2, p = 0.001) and low DLCO (HR = 2.4, p = 0.028). On
the other hand, independent prognostic factors for
overall survival in the younger group were low DLCO
(HR = 5.3, p = 0.004), male gender (HR = 5.3, p = 0.026),
and IPF (HR = 14.1, p < 0.001).
Disease-free survival showed unexpectedly discour-
aging results for the elderly group (5-year disease-free
survival rate; 53.3 vs. 80.2 %, p < 0.001). In the multivari-
ate analysis, independent prognostic factors for disease-
free survival were elderly age (HR = 2.4, p < 0.001), male
Table 1 Patient clinicopathologic features and surgical procedures
Elderly group (n = 285) Younger group (n = 1055) p
Median age, years (range) 73 (70–86) 58 (20–69) <0.001*
Sex, male, n (%) 201 (70.5) 642 (60.9) 0.003**
Pathologic stage, n (%) <0.001**
Stage IA 119 (41.7) 527 (59.4)
Stage IB 166 (58.3) 428 (40.6)
Histologic subtype, n (%) <0.001**
Adenocarcinoma 171 (60) 824 (78.1)
Squamous cell carcinoma 105 (36.8) 211 (20)
Large cell neuroendocrine carcinoma 9 (3.2) 20 (1.9)
Extent of resection, n (%) 0.280**
Sublobar resection 23 (8.1) 82 (7.8)
Lobectomy 250 (87.7) 947 (89.7)
Bilobectomy 12 (4.2) 26 (2.5)
Type of operation, n (%) <0.001**
Video-assisted thoracoscopic surgery 127 (44.6) 656 (62.2)
Thoracotomy 158 (55.4) 399 (37.8)
*p value estimated by the Wilcoxon signed-rank test
**p value estimated by Pearson’s chi-square test
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gender (HR = 1.7, p = 0.017), IPF (HR = 4.0, p < 0.001),
low DLCO (HR = 2.0, p = 0.006), and stage IB (HR = 2.1,
p < 0.001). In the subgroup analysis, independent prog-
nostic factors for disease-free survival in elderly patients
were male gender (HR = 2.6, p = 0.007) and low DLCO
(HR = 2.1, p = 0.03). Incidence of recurrence within 2 years
was also significantly higher in elderly group than in youn-
ger group (13.7 vs. 5.7 %, p < 0.001). Independent risk fac-
tors for recurrence were elderly age (HR = 3.4, p = 0.001)
and pathologic stage IB over IA (HR = 4.3, p < 0.001).
Short- and long-term outcomes of stage I lung cancer ac-
cording to the age group were summarized in Table 3, and
results of multivariate analysis in elderly group were also
demonstrated in Table 4.
To rule out the effect of functional and pathologic dif-
ferences other than age between two groups, further pair
matching analysis was performed for this unexpected
high incidence of recurrence rate in elderly patients. Pair
matching analysis was performed by propensity score
matching, and 285 pairs of elderly and younger patients
were matched 1:1. The clinical variables used for match-
ing were gender, comorbidities, preoperative labs, and
pulmonary function tests. Pathologic variables were also
matched and included cancer stage and histologic sub-
type. The surgical variables included extent of pulmon-
ary resection and type of operation.
Analysis of the cumulative recurrence rate after pul-
monary resection between the elderly and the matched
younger controls to evaluate lung cancer-specific long-
term outcome still showed discouraging results for the
elderly group. Five-year overall survival rates in the un-
matched younger, matched younger, and elderly groups
were 91.1, 89.5, and 69.0 %, respectively. Five-year disease-
free survival rates in the younger and elderly groups were
80.2 %, 75.0 % and 53.3 %, respectively. Three-year cumu-
lative recurrence rates of the younger and elderly groups
were 16.0 and 23.2 %, respectively (p = 0.001), and stage IB
(HR = 1.7, p = 0.035) was the only independent risk factor
in elderly patients. However, there was no significant dif-
ference between the younger group and the elderly group
in loco-regional recurrence rate (11.0 vs. 11.3 %, p =
0.586). Only distant recurrence rate was significantly dif-
ferent between the younger group and the elderly group
(5.6 vs. 13.4 %, p < 0.001). The most common extra-
thoracic sites of distant recurrence were brain (n = 15),
liver (n = 10), and bone (n = 10), for which the incidence
of metastasis was significantly higher in the elderly group
(3.5 vs. 8.8 %, p = 0.009). Comparison of elderly patients
and matched younger control was demonstrated in sup-
plementary data.
Discussion
Several large population studies have examined early re-
sults after pulmonary resection in elderly patients and
reported that the early mortality among elderly patients
was significantly greater [8–10]. In a recent study based
on a large French national database performed by Rivera
et al., postoperative mortality was significantly higher in
elderly patients at every end point compared with youn-
ger controls (30-day mortality; 3.6 vs. 2.2 %, p = 0.010,
90-day mortality; 4.7 vs. 2.5 %, p < 0.001), and the au-
thors pointed out that the 90-day mortality rate seems
to better represent real mortality risk than the 30-day
mortality rate [11], which was supported by our data
(30-day mortality; p = 0.014, 90-day mortality; p < 0.001,
Table 3). On the other hand, Cerfolio and colleagues re-
ported in their nested case-control study that there was
no significant difference in 30-day or in-hospital mortal-
ity between younger and elderly patients (3.8 vs. 2.2 %,
p = 0.20) [12]. However, the proportion of male patients
Fig. 1 Kaplan-Meier curve of overall and disease-free survival in
younger and elderly groups. a Five-year overall survival rates in the
younger and elderly groups were 91.1 and 69.0 %, respectively.
b Five-year disease-free survival rates in the younger and elderly
groups were 80.2 and 49.3 %, respectively
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was significantly lower in their elderly group after match-
ing, and other comorbidities that might be associated with
early outcome in elderly patients were not included as
matching variables. Recently, Rueth et al. reported that
male gender, higher comorbidity index and age older than
75 years significantly increased postoperative mortality [13].
These discouraging results of elderly group might have
been caused by the fragility involved with aging process.
Fragility, which is often defined as unintentional weight
loss, self-reported exhaustion, muscular weakness, slow
walking speed, and low physical activity, is identified as an
independent risk factor for major morbidity, mortality, pro-
tracted length of stay, and institutional discharge [14, 15].
To compare long-term outcome, Sigel et al. analyzed
27,859 cases of stage I NSCLC from surveillance, epi-
demiology, and end results (SEER) data and showed that
the overall 5-year survival rate declined slightly with in-
creasing age in male patients who underwent surgical re-
section (age groups <60, 61–69, 70–79, ≥80; 69.2, 66.0,
62.8, and 63.5 %, respectively) but remained similar
across all ages [16]. Cerfolio and colleagues reported that
5-year overall survival in their elderly group (≥70 years)
was 78 %, which was surprisingly better than the rate in
their younger group (69 %, p = 0.01) with stage I NSCLC
[12]. Nonetheless, generally speaking, chronological age
itself is still considered a major risk factor in long-term
follow-up. In a study based on SEER conducted by Mery
et al. [17] and retrospective matched study by Good-
game et al. [18], both authors reported worse overall sur-
vival for elderly patients.
Few studies have examined the association between lung
cancer recurrence and age. Maeda et al. analyzed risk fac-
tors for the recurrence of stage I NSCLC; finding that old
age (≥65 years) was a risk factor with borderline signifi-
cance for cancer recurrence in a multivariate analysis (p =
0.051) [19]. In contrast, Goodgame and colleagues re-
ported that cancer recurrence rate in elderly patients was
the same as that in younger patients (3-year cumulative
Table 3 Short- and long-term outcomes of stage I non-small cell lung cancer
Elderly group (n = 285) Younger group (n = 1055) p
Short-term results
30-day mortality, n (%) 6 (2.2) 0 0.014*
90-day mortality, n (%) 11 (3.9) 5 (0.5) <0.001*
Complication rate, % 47.7 26.9 <0.001*
Hospital stay, days 11.2 ± 12.2 8.0 ± 8.5 <0.001**
Long-term results
5-year overall survival rate, % 69.0 91.1 <0.001***
5-year disease-free survival rate, % 53.3 80.2 <0.001***
Recurrence rate within 2 years, % 13.7 5.7 <0.001*
*p value estimated by Pearson’s chi-square test: **p value estimated by Student’s t test 2; ***p value estimated by the log-rank test
Table 2 Prognostic factors for overall survival
Univariate analysis (log-rank test) Multivariate analysis (Cox hazard model)
Prognostic factors HR (95 % CI) p HR (95 % CI) p
Age group 4.2 (3.1–5.6) <0.001 3.6 (2.1–6.2) <0.001
Low DLCOa 5.2 (3.2–8.7) <0.001 3.8 (2.1–7.1) <0.001
IPFb 13.8 (7.6–25.0) <0.001 4.8 (2.1–10.8) <0.001
Male 2.6 (1.7–3.9) <0.001 3.2 (1.4–7.1) 0.005
Pulmonary Tbc.c 1.5 (1.1–2.2) 0.039 -
Hypertension 1.39 (1.1–1.9) 0.036 -
Diabetes mellitus 1.9 (1.3–2.8) <0.001 -
Decreased kidney functiond 2.7 (1.1–7.2) 0.043 -
Stage IB 1.9 (1.4–2.6) <0.001 -
Lobectomy/bi-lobectomy 1.7 (1.1–2.8) 0.033 -
Thoracotomy 2.8 (2.0–3.9) <0.001 -
aExpected diffusing capacity for carbon monoxide less than 70 % of prediction
bInterstitial pulmonary fibrosis
cPrevious history of pulmonary tuberculosis
dPreoperative creatinine level higher than 1.5 mg/dL
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recurrence rate; 19 vs. 20 %, p = 0.425) [18]. In our study,
the recurrence rate in elderly patients was significantly
higher than in younger patients (recurrence rate within
2 years; 13.7 vs. 5.7 %, p < 0.001). This finding suggests
that lung cancer in elderly patients is not always less viru-
lent. Another explanation for more frequent distant failure
in elderly patients might be less aggressive mediastinal
lymph node dissection. Recently, Wang et al. reported that
elderly patients without radical mediastinal lymphadenec-
tomy experienced more frequent distant relapse compared
to those who did undergo the procedure [20]. However, as
shown in this study with systemic lymph node dissection
in any age group, the cancer-free survival in the elderly
was lower than in the younger patients. Therefore, more
frequent and meticulous follow-up should be needed in
the elderly group.
In this study, early and long-term outcomes in elderly
patients were worse than expected, and decreased DLCO
was the common predictive factor for poor results both in
early and long-term outcomes. The importance of DLCO
has been recognized in many gerontologic studies. Yano et
al. reported that old age (≥70 years), pneumonectomy, and
DLCO less than 70 % of predicted significantly increased
life-threatening morbidity after pulmonary resection for
lung cancer [21]. Ferguson et al. studied patients who
underwent surgery for lung cancer and showed that the
incidence of postoperative complications doubled in case
of low diffusion capacity (DLCO less than 80 % of pre-
dicted) [22–24]. For long-term outcome, it is not fully
understood whether low diffusion capacity affects progno-
sis. Ferguson et al., in their study mentioned above, re-
ported that low FEV1 did not affect long-term prognosis,
but DLCO less than 60 % of predicted significantly
worsened overall survival [24]. Another study reported
that a DLCO less than 40 % best predicted decreased sur-
vival from causes other than cancer within stage I lung
cancers [25]. Therefore, surgery for elderly patients with
low diffusion capacity may require extra caution or re-
consideration of alternative treatments, including lim-
ited resection or radiotherapy [26–28]. In this study,
patients with DLCO less than 80 % or less than 60 %
showed significantly worse outcome in overall survival
(HR = 4.6, p < 0.001 and HR = 17.9, p < 0.001, respect-
ively). Overall survival according to DLCO is presented
in Fig. 2. According to the results of this study, pul-
monary resection for lung cancer in elderly patients
Table 4 Multivariate analyses of risk and prognostic factors for short- and long-term results in elderly patients
Predictive factors OR/HR (95 % CI) p
Short-term outcomes
30-day mortality DLCO less than 70 % of prediction 17.1 (1.46–199) 0.024
90-day mortality DLCO less than 70 % of prediction 8.47 (1.11–64.6) 0.039
Complication rate Male gender 7.80 (3.10–19.6) <0.001
DLCO less than 70 % of prediction 3.51 (1.03–12.0) 0.045
Hospital stay Open thoracotomy 6.75 (2.41–11.1) 0.003
DLCO less than 70 % of prediction 8.64 (1.88–15.4) 0.013
Long-term outcomes
5-year overall survival Squamous cell carcinoma 3.18 (1.56–6.48) 0.001
DLCO less than 70 % of prediction 2.37 (1.10–5.14) 0.028
5-year disease-free survival Male gender 2.57 (1.29–5.09) 0.007
DLCO less than 70 % of prediction 2.07 (1.07–4.00) 0.030
Recurrence rate within 2 years Stage IB 1.7 (1.04–2.75) 0.035
DLCO: expected diffusing capacity for carbon monoxide
OR: odd ratio from logistic regression model for short-term outcomes
HR: hazard ratio from Cox proportional hazard model for long-term outcomes
95 % CI: 95 % confidential interval
Fig. 2 Overall survival according to the level of diffusion capacity.
Five-year overall survival rates in stage I lung cancer were significantly
associated to the level diffusion capacity with hazard ratio of 0.11 (95 %
CI, 0.05–0.24) in the group with DLCO less than 80 % and with hazard
ratio of 0.06 (95 % CI, 0.02–0.13) in the group with DLCO less than 60 %
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was far more risky than in younger patients. It is diffi-
cult to point out the risks of being old, but we presume
that it comes from complex reasons, such as fragility to
postsurgical stress and life expectancy of belonging so-
ciety, and a searching analysis of the elderly patients are
required in future studies. Until then, elderly patients who
undergo pulmonary resection for lung cancer might re-
quire more rigorous application of operability than youn-
ger patients. Especially with the patients with decreased
DLCO, additional assessments such as exercise pulmonary
function test should be performed prior to surgery, and if
the patients are judged to be unsuitable for surgery, alter-
native treatments should be considered. For patients who
are medically inoperable for early lung cancer, stereotactic
body radiation therapy (SBRT) has been widely applied
and reported to be highly effective at controlling the pri-
mary tumor without serious toxicity. Radiation Therapy
Oncology Group 0236 trial, which enrolled inoperable 59
patients with T1-2 lung cancer, showed 3-year survival of
55.8 % after SBRT and high rates of local tumor control
(3-year primary tumor control rate of 97.6 %.) [29]. Onishi
et al. reported even better results, and the 5-year overall
survival rates in this study showed 72 and 62 % for stage
IA and IB, respectively [30].
This study was a retrospective study and has associ-
ated limitations. Potential confounders affecting results
after pulmonary resection in younger and elderly groups
were minimized by matching clinicopathologic variables
and surgical factors. Another limitation is that other
known independent factors from previous studies, such
as preoperative serum carcinoembryonic antigen level or
lymphovascular invasion in pathologic reports, were not
evaluated due to incomplete availability of these parame-
ters in our database [31, 32]. Also, socioeconomic pos-
ition of patients, which is also another important
predictive factor in cancer treatment, was not considered
in this study [33].
Conclusions
In conclusion, elderly patients with stage I NSCLC showed
unsatisfying results in both short- and long-term outcomes.
Especially, elderly patients with low DLCO are at risk for
significantly worse outcome, indicating that patient selec-
tion should include assessment of pulmonary function, in-
cluding DLCO, and also, more frequent following up
should be needed.
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